Novartis Expands U.S. Manufacturing with $23 Billion Investment, Advances IgAN Portfolio
Feb 19, 2026
Novartis commits $23 billion to U.S. manufacturing expansion with new facilities in North Carolina, California, and Florida, while advancing its immunoglobulin A nephropathy drug portfolio with positive Phase III results for Vanrafia.